Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05031858Not ApplicableUnknown

Effect of Vojta Therapy on Covid-19 Respiratory Disease

Role: lead

NCT04689841Not ApplicableUnknown

Influence of Short-term Vojta Therapy on the Gait in Healthy Adult Subjects.

Role: lead

NCT03890965Not ApplicableCompleted

Effects of the Application of a Reflex Locomotion Program in the Neurological Hand

Role: lead

NCT03887507Not ApplicableCompleted

Vojta Therapy in Multiple Sclerosis.

Role: lead

All 4 trials loaded